A detailed history of Bellevue Group Ag transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Bellevue Group Ag holds 610,000 shares of CRSP stock, worth $28.8 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares
610,000
Previous 617,649 1.24%
Holding current value
$28.8 Million
Previous $33.4 Million 14.08%
% of portfolio
0.48%
Previous 0.56%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$44.62 - $62.75 $341,298 - $479,974
-7,649 Reduced 1.24%
610,000 $28.7 Million
Q2 2024

Aug 14, 2024

SELL
$51.17 - $68.18 $117,742 - $156,882
-2,301 Reduced 0.37%
617,649 $33.4 Million
Q1 2024

May 15, 2024

SELL
$60.67 - $89.12 $17 Million - $25 Million
-280,450 Reduced 31.15%
619,950 $42.3 Million
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $77,240 - $144,360
2,000 Added 0.22%
900,400 $56.4 Million
Q3 2023

Nov 14, 2023

SELL
$45.39 - $59.0 $40,851 - $53,100
-900 Reduced 0.1%
898,400 $40.8 Million
Q2 2023

Aug 14, 2023

SELL
$43.47 - $67.77 $21,735 - $33,885
-500 Reduced 0.06%
899,300 $50.5 Million
Q1 2023

May 15, 2023

SELL
$41.0 - $56.12 $488,105 - $668,108
-11,905 Reduced 1.31%
899,800 $40.7 Million
Q4 2022

Feb 14, 2023

SELL
$39.19 - $65.67 $650,554 - $1.09 Million
-16,600 Reduced 1.79%
911,705 $37.1 Million
Q3 2022

Nov 14, 2022

BUY
$61.1 - $83.78 $384,930 - $527,814
6,300 Added 0.68%
928,305 $60.7 Million
Q2 2022

Aug 11, 2022

SELL
$43.23 - $73.83 $211,826 - $361,767
-4,900 Reduced 0.53%
922,005 $56 Million
Q1 2022

May 13, 2022

SELL
$53.19 - $79.24 $2.54 Million - $3.79 Million
-47,779 Reduced 4.9%
926,905 $58.2 Million
Q3 2021

Nov 12, 2021

BUY
$110.2 - $156.64 $859,560 - $1.22 Million
7,800 Added 0.81%
974,684 $109 Million
Q2 2021

Aug 12, 2021

SELL
$100.84 - $161.89 $1.16 Million - $1.86 Million
-11,500 Reduced 1.18%
966,884 $157 Million
Q1 2021

May 12, 2021

BUY
$110.72 - $210.04 $7.61 Million - $14.4 Million
68,700 Added 7.55%
978,384 $119 Million
Q4 2020

Feb 16, 2021

SELL
$79.67 - $173.23 $3.15 Million - $6.86 Million
-39,578 Reduced 4.17%
909,684 $139 Million
Q3 2020

Nov 16, 2020

BUY
$78.5 - $100.64 $11.7 Million - $15 Million
148,800 Added 18.59%
949,262 $79.4 Million
Q1 2020

May 14, 2020

BUY
$33.68 - $62.53 $2.36 Million - $4.38 Million
70,000 Added 9.58%
800,462 $33.9 Million
Q4 2019

Feb 14, 2020

SELL
$36.68 - $73.13 $3.91 Million - $7.8 Million
-106,700 Reduced 12.75%
730,462 $44.5 Million
Q3 2019

Nov 14, 2019

BUY
$40.99 - $52.56 $1.09 Million - $1.4 Million
26,700 Added 3.29%
837,162 $34.3 Million
Q2 2019

Aug 14, 2019

BUY
$35.45 - $48.2 $28.7 Million - $39.1 Million
810,462 New
810,462 $38.2 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.69B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.